Sector News

Calico loses its second executive in 4 months as Daphne Koller quits

March 5, 2018
Life sciences

Alphabet’s supersecretive Calico Labs is losing its top artificial intelligence researcher as Chief Computing Officer Daphne Koller moves on to greener pastures.

“I have decided to leave Calico to pursue other professional opportunities,” Koller said in an emailed statement to Bloomberg. “I very much enjoyed my time at Calico, and have the greatest respect for the Calico team and their important and aspirational mission.”

Koller signed on with Calico in August 2016 to lead its machine learning and computational biology team. Her job? To build a team that can analyze large volumes of health data and change the way we think about aging and disease.

She joined the company from Coursera, the education tech outfit she founded in 2012.

In addition to applying existing machine learning techniques to biological data, she also intended to develop new kinds of machine learning that can change human health, she told FierceBiotech in September that year.

And her path at Calico was uncharted—because her approach was data-driven, the specific indications Calico would tackle hinged on which data are produced and what her team learned from analyzing it.

“Daphne has been instrumental in helping to build our machine learning and computing infrastructure and has made many important contributions as we aim to bring the vast capabilities of machine learning to bear on advancing our understanding of the biological mechanisms by which we age,” Calico spokesman Neil Cohen said, according to Bloomberg.

Koller’s departure is Calico’s second high-profile exit in recent months. In November, its R&D chief, Hal Barron, jumped ship to take the chief scientific officer position at GlaxoSmithKline.

The Big Pharma hired Barron, who now heads a new GSK office in San Francisco, to shake up R&D as it has seen few approvals or exciting research updates in the last few years.

By Amirah Al Idrus

Source: Fierce Biotech

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).